tbuckley/cabot-search huggingface dataset:
Heterogeneous response and irAE patterns in advanced melanoma patients treated with anti-PD-1 monotherapy from different ethnic groups: Subtype distribution discrepancy and beyond.
Authors: Xue Bai, Henry Quach, Christopher G Cann, Michael Zhang, Michelle S. Kim, Gyulnara G. Kasumova, Lu Si, Bixia Tang, Chuanliang Cui, Xiaoling Yang, Xiaoting Wei, Justine Vanessa Cohen, Donald P. Lawrence, Tatyana Sharova, Dennie T. Frederick, Keith Flaherty, Ryan J. Sullivan, Genevieve Marie Boland, Douglas Buckner Johnson, Jun Guo
Journal: Journal of Clinical Oncology (2020)

10020 Background: Programmed cell death receptor-1 (PD-1) monotherapy is the standard first line therapy for advanced cutaneous melanoma, with efficacy, toxicity, and their correlations well established. Yet these remain poorly characterized for non-Caucasians and for certain rarer melanoma subtypes. Methods: Clinical data from melanoma patients treated with anti-PD-1 monotherapy between 2009 and 2018 was collected retrospectively from three independent institutions from the US and China. Tumor response, survival outcome, and organ/system-specific immune-related adverse effects (irAEs) were directly compared between different subgroups. Results: Among 626 patients, 411 were Caucasian, 214 non-Caucasian; 369 had cutaneous melanoma, and 257 other subtypes. Both ethnicity and melanoma subtype were independently associated with benefit and irAEs. In multivariate analyses, Caucasians had significantly higher objective response rate (ORR) (OR 2.0, 95% CI 1.1-3.5), but this did not translate into a survival advantage (PFS, HR 0.8, 95% CI 0.6-1.1; OS, HR 1.0, 95% CI 0.7-1.4); melanoma of unknown primary shared similar response and survival profile with cutaneous, while acral (ORR, OR 0.4, 95% CI 0.2-0.9; PFS, HR 1.6, 95% CI 1.1-2.2; OS, HR 1.3, 95% CI 0.8-1.9), mucosal (ORR, OR 0.4, 95% CI 0.2-0.9; PFS, HR 1.4, 95% CI 1.0-2.0; OS, HR 1.7, 95% CI 1.1-2.6) and ocular (ORR, OR 0.1, 95% CI 0-0.6; PFS, HR 2.3, 95% CI 1.4-3.6; OS, HR 2.2, 95% CI 1.3-3.6) melanomas had inferior outcomes. Non-Caucasian cutaneous patients had a significantly worse ORR than Caucasians with cutaneous melanoma (P &lt; .01). Distinct irAE patterns were observed, exemplified by lower incidence of most irAEs (although more frequent pneumonitis) in Caucasians, and higher and lower liver irAE incidence in ocular and mucosal melanomas, respectively. Endocrine, musculoskeletal and skin irAEs were associated with improved PFS and OS across ethnicities and nearly all melanoma subtypes, whereas heterogeneity existed for other irAE types. Conclusions: Ethnicity and melanoma subtype are associated with distinct response patterns, survival outcomes, and irAE profiles in the setting of anti-PD-1 monotherapy. More research is needed to elucidate the molecular and immunologic determinants of these variable outcomes.
A phase Ib study of abemaciclib in combination with pembrolizumab for patients (pts) with stage IV Kirsten rat sarcoma mutant <i>(</i>KRAS<i>-</i>mut) or squamous non-small cell lung cancer (NSCLC) (NCT02779751): Interim results.
Authors: Jean-Louis Pujol, Johan F. Vansteenkiste, Luis G. Paz-Ares, Vanesa Gregorc, Julien Mazieres, Mark M. Awad, Pasi A. Janne, Michael Jon Chisamore, Anwar Hossain, Yanyun Chen, Joseph Thaddeus Beck
Journal: Journal of Clinical Oncology (2020)

9562 Background: Abemaciclib is an orally administered, selective small molecule cyclin-dependent kinase 4 and 6 inhibitor. In preclinical models, abemaciclib induced intratumor immune inflammation and synergized with PD-1 blockade to enhance antitumor efficacy in anti-PD-L1 refractory disease. Here, we report the safety and antitumor activity of abemaciclib plus the approved NSCLC treatment pembrolizumab in 2 cohorts for pts with nonsquamous and squamous NSCLC. Methods: Eligible pts for this nonrandomized, open-label, multicohort, phase 1b study were either chemotherapy-naive with ≥ 1% tumor cell (TC) PD-L1 staining, KRAS-mut nonsquamous NSCLC (Cohort A) or had a squamous subtype and received ≤ 1 prior platinum-containing chemotherapy regimen (Cohort B) for metastatic NSCLC. Primary endpoint was safety; secondary objectives included objective response rate (ORR), progression-free survival (PFS), and overall survival (OS). Results: Twenty-five pts with NSCLC were enrolled in each cohort. Most pts (68%) in Cohort B had received 1 prior line of chemotherapy. Safety profiles observed in both cohorts were largely consistent with previous reports for abemaciclib and pembrolizumab monotherapy. Grades 3/4 AEs in Cohorts A and B, respectively, included ALT increase (6 pts [24%]/ 0 pts), diarrhea (3 pts [12%]/ 0 pts), neutropenia (3 pts [12%]/ 0 pts), and pneumonitis (3 pts [12%]/ 1 pt [4%]). Six pts in Cohort A (24%) and 2 pts in Cohort B (8%) had a confirmed partial response for a disease control rate (CR+PR+SD) of 52% and 64%, respectively. In Cohort A, the ORR in pts with strong (≥50% TC) PD-L1 staining (n = 13) was 31% vs. 17% in pts with weak (1-49% TC) PD-L1 expression (n = 12). Median PFS and OS were 7.6 months (95% CI: 1.6, NR) and 22.0 months (95% CI: 9.9, NR) in Cohort A and 3.3 months (95% CI: 1.4, 5.2) and 6.0 months (95% CI: 3.7, 13.1) in Cohort B, respectively. Conclusions: Abemaciclib plus pembrolizumab resulted in a numerical higher rate of transaminase elevations and pneumonitis. Antitumor activity was remarkable in the KRAS-mut nonsquamous NSCLC but not noticeably higher as compared to historical data for pembrolizumab monotherapy. Clinical trial information: NCT02779751 .
Novel CTC test followed by iodine therapy for the terminal stage of cancer patients.
Authors: Taro Shirakawa
Journal: Journal of Clinical Oncology (2020)

e15661 Background: 5 years of survival rate of stage IV cancer patients have kept poor for these 30 years. This is mainly due to inevitability of anti-cancer drugs for them because of multi-organ metastasis. We developed a novel CTC technique to identify CTCs responsible for metastasis, and provided a method to kill those dangerous cells by Iodine therapy. Methods: We did 314 CTC tests, and 53 patients received it more than twice (average prognosis of 4.5 months). Our CTC tests by flouring 4cc blood of the patients into a special device with &gt; 50,000 pores of 8μ diameters, this device can only catch CTCs. We also stained with cytokeratin and vimentin anti-bodies (see table). Iodine water was made of 10,000 ppm of NaI with certain numbers of additional chemicals. This preclinical trial was accepted by our ethical committee. Results: We developed a novel CTC technique to catch 95% of CTCs and identified 3 types of CTCs (see table). Without any therapy, type 1 cells disappeared, while all patients with type 2 cells died within a couple of months, this may be due to EMT (epithelial mesenchymal transformation) on them. We tested certain numbers of ant-cancer drugs and found that no drugs can kill type 2 cells, only stable Iodine water provided by our clinic can kill type 2 cells perfectly within two months, and 51 out of 53, the terminal stage of patients can survive more than a year. Conclusions: Novel CTC test can identify 3 types of CTCs and type 2 cells can be responsible for the poor survival of terminal stage cancer patients because they are responsible for metastasis, and anti-cancer drugs cannot kill them. It has been well-known that Iodine induces PPARγ which can promote apoptosis of type 2 cells and inhibit EMT. Iodine may improve their poor prognosis.[Table: see text]
Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7-9 years of age
Authors: Rowan Janet A, Rush Elaine C, Plank Lindsay D, Lu Jun, Obolonkin Victor, Coat Suzette, Hague William M, 张贝, 巩纯秀
Journal: BMJ (2018)

目的
比较妊娠糖尿病（GDM）妇女在怀孕期间随机分为二甲双胍（±胰岛素）治疗组或胰岛素治疗组治疗后7~9岁子代的机体成分和代谢的随访结果。


设计及方法
通过人体测量、生物电阻抗分析（BIA）、双能X线吸收测量（DXA）、磁共振成像（MRI）（n=92/99）和禁食（n=82/99）对阿德莱德的7岁儿童（n=109/181）和奥克兰的9岁儿童（n=99/396）进行评估


结果
在阿德莱德研究组中，母亲情况在初始登记时相似。随机分为二甲双胍治疗组，较胰岛素治疗组的血糖高（P=0.002）且婴儿出生体重>第90百分位的数量更多（20.7%∶5.9%；P=0.029）。在7岁时，子代的测量结果则无明显差异。在奥克兰研究组，随机服用二甲双胍的妇女体质指数（BMI）较高（P=0.08），但是治疗过程中体重增加较少（P=0.07）。子代出生时测量结果相似，而9岁时二甲双胍治疗组的子代体重、臂围、腰围、腰围/身高较高（P<0.05）；BMI、三头肌褶皱（P=0.05）；DXA脂肪量和肌肉量；MRI腹部脂肪体积（P=0.051）的测量结果较高。通过DXA和BIA发现体脂百分比在2个治疗组中相似。MRI发现腹部脂肪百分比（内脏脂肪组织、皮下脂肪组织和肝脏）相似。空腹血糖、甘油三酯、胰岛素、胰岛素抵抗、糖化血红蛋白、胆固醇、肝转氨酶、瘦素和脂联素亦相似。


结论
二甲双胍或胰岛素治疗的妊娠期糖尿病妇女7~9岁的子代全身体脂百分比和腹部体脂百分比是相似的。但二甲双胍治疗组儿童在9岁时体格测量显著高。说明二甲双胍可能与胎儿的环境因素相互作用，会影响子代。
Major histocompatibility complex class 1 (MHC1) loss among patients with glioblastoma (GBM).
Authors: Michael Castro, Bence Sipos, Natalia Pieper, Saskia Biskup
Journal: Journal of Clinical Oncology (2020)

e14523 Background: Immune evasion represents a hallmark behavior of cancer and may occur through many mechanisms. Among these, intact tumor antigen presentation at the cell surface is a fundamental prerequisite to achieving successful adaptive immunotherapy. The loss of MHC1 expression due to molecular events, including mutation, deletion, or epigenetic silencing of B2M is commonly acquired during immunotherapy. On the other hand, molecular events affecting antigen presentation machinery may be present prior to immunotherapy administration. Among these, TP53 mutations causing loss of ERAP1 and TAP1 expression compromise transport of MHC1 molecules from the endoplasmic reticulum to the cell surface and mutant peptide integration into the HLA context resulting in absent antigen presentation. Thus far, clinical trials of PD-1/L1 agents have failed to demonstrate a benefit for GBM patients and responses are seen only among a minority. Hence, we set out to assess the integrity of MHC1 expression by using immunohistochemistry. Methods: Immunohistochemical (IHC) stains for HLA, B and C were developed and validated with internal controls. Staining intensity and location (membrane-bound or cytoplasmic) was evaluated semi-quantitatively. The first 10 consecutive patients with GBM who were referred for neoepitope vaccine were evaluated. Results: Absent staining was seen among 6/10, negligible, or faint staining was present in 2, and only 2 tumors demonstrated intact membrane-bound expression. Conclusions: In addition to low tumor mutation burden and an immunosuppressive tumor microenvironment, MHC1 loss is a frequent event among patients with GBM, and may be a dominant cause of immunotherapy failure for as many as 80% of patients. Thus, development of strategies to reverse this loss may be an essential component of successful adaptive immunotherapy for this disease. These data suggest that routine assessment of MHC1 should become a component of eligibility checking for GBM patients being considered for an MHC-restricted approaches. [Table: see text]
点评:关于基层医疗国际分类
Authors: 梁万年
Journal: BMJ (2004)

基层医疗国际分类( international classification of primary care , ICPC),是1987 年由世界家庭医生组织(WONCA)分类委员会研究出版的适合于基层医疗的一个新的分类系统.作为基层医疗标准化的分类工具,ICPC能够对健康档案中SOAP四个要素中的三个,即患者的就诊原因(S)、健康问题(A)和健康问题处理计划(P)进行分类和编码.同时,该分类系统还涵盖了对全科医疗中常见的心理和社会问题的分类.此分类系统的应用可以使信息标准化,因此增进了各国间基层医疗信息进行比较的可操作性和可比性.1992年WONCA正式提出了使用该分类系统,受到世界各国全科医学界的普遍关注和欢迎.目前,它已被翻译成20余种语言,在世界上得到了广泛的研究和应用.1998年ICPC经修订后出版,称为ICPC-2.我国大陆于1997年开始正式接触该分类系统,并将其翻译为中文,在部分社区中进行全科医疗健康档案记录资料的分类和编码尝试。
单味鸡内金治疗巨大胃石症一例
Authors: 李合章
Journal: BMJ (2004)

患者女,26岁,2001年8月因间断上腹部疼痛5年,突然晕厥就诊.伴反酸,多于进食半小时后发作,时有黑便;入院前5个月,上腹部疼痛加剧,黑便次数增多,常按胃炎口服药物治疗(具体不详).平日喜食硬柿子、白薯及黑枣等食物.查体:身体瘦弱,脐下可扪及6 cm×7 cm×6 cm包块,质硬,表面光滑,边缘清楚,移动性大,有轻度触痛.经门诊纤维内窥镜和胃钡餐检查,胃内有一巨大充盈缺损区,推之可移动.除外其他疾病后诊断胃石症。
Discordance between molecular subtyping from pre- and post-neoadjuvant chemotherapy (NACT) biopsy specimens in a Brazilian breast cancer cohort.
Authors: Monique Celeste Tavares, Luciana de Moura Leite, Marcelle Goldner Cesca, Poliana de Andrade, Rafaela Pirolli, Mariana Pinheiro Xerfan, Fernanda A. Oliveira, Sinara Figueiredo Silva, Camilla Albina Zanco Fogassa, Bruna Raphaeli Silva Mattos, Fernando Augusto Batista Campos, Solange Moraes Sanches, Vladmir Claudio Cordeiro De Lima
Journal: Journal of Clinical Oncology (2020)

e12649 Background: Discordance between immunohistochemistry (IHC) and molecular subtyping from pre and post neoadjuvant chemotherapy (NACT) biopsy specimens in breast cancer (BC) patients (pts) varies in the literature. This information could have prognostic and treatment implications. To evaluate the clinicopathologic characteristics and prognostic factors in pts with localized breast cancer treated with NACT who had IHC repeated in the post treatment biopsies. Methods: We retrospectively reviewed all BC pts treated with NACT at our service (2007 – 2018). Descriptive statistics were used to describe the population. Survival curves were estimated by Kaplan-Maier method, prognostic factors adjusted by Cox regression model. Results: 607 consecutive pts were treated with NACT at our service. From those, 178 (29.3%) had a pathological complete response, 420 (69.2%) had residual disease and 9 (1.5%) had an unknown status. For 95 pts, the IHC was repeated in the pathological specimen, with a change in the molecular subtype in 26 (27.3%) cases. 10 luminal pts lost the hormonal receptor expression and changed to triple negative, 6 luminal B became luminal A, 3 luminal A became luminal B, 6 pts lost the her2 amplification and 1 pt gained a her2 amplification. This 95 pts cohort had a median desease free survival (DFS) of 71 months (m) and an overall survival (OS) of 137m. Pts who had a change in their molecular subtype after NACT had a DFS of 52 m vs 71m (p .26) and OS 86m, not significantly different from those who maintained the same status (p .23). Conclusions: A little more than one quarter of the pts that had repeated post NACT IHC had a change in the molecular subtype, especially with loss of hormonal receptors of luminal tumors, that became triple negative. That did not translated into significantly worse survivals.
Is there a benefit of oxaliplatin in neoadjuvant treatment of locally advanced rectal cancer? An updated meta-analysis.
Authors: Gaetan Des Guetz, Thierry Landre, Anne Larrouy, Yves Panis, Jean F. Morere, Muriel Mathonnet, Laurent Quero
Journal: Journal of Clinical Oncology (2020)

4098 Background: Neoadjuvant fluoropyrimidine (5FU or capecitabine)-based chemoradiotherapy (CRT) has been considered the standard of care for locally advanced rectal cancer (LARC). Whether addition of oxaliplatin (OXP) will further improve clinical outcomes is still unclear. Methods: To identify clinical trials combining oxaliplatin in preoperative CRT or perioperative chemotherapy for LARC published until December 2019, we searched PubMed, the Cochrane Library. We also search for relevant ASCO conferences. Primary endpoint was Disease-Free-Survival (DFS). Data were extracted from every study to perform a meta-analysis using Review Manager (version 5.3). Results: A total of 7 Randomized Clinical Trials (ACCORD-12, CARO-AIO-04, FOWARC, JIAO, NSABP, PETACC-6 and STAR-01) with 5782 stage II or III rectal cancer patients were analysed, including 2727 patients with OXP + 5FU regimen and 3055 patients with 5FU alone regimen. Compared with 5FU-based regimen group, OXP-based regimen group improved DFS (HR = 0.90, 95% CI: 0.81−0.99, P = 0.03) and increased pathologic Complete Response (OR = 1.21, 95% CI: 1.07−1.37, P = 0.002). Patients treated with OXP-regimen had significantly less metastatic disease (OR = 0.79; 95% CI, 0.67 to 0.94; p = 0.007). Considering Adverse Events (AEs), there was more grade 3-4 diarrhoea with OXP (OR = 2.41, 95% CI: 1.74−3.32, P &lt; 0.00001). However, there were no significant differences grade 3-4 haematologic AEs (OR = 1.16, 95% CI: 0.87−1.57, P = 0.31). Conclusions: Combining oxaliplatin with capecitabine or 5FU in preoperative chemoradiotherapy or perioperative chemotherapy seems beneficial significantly and improved DFS. It remains necessary to identify which patients benefit most from the addition of oxaliplatin.
鼻内镜下低温等离子刀腺样体切除术的临床研究
Authors: 叶林峰, 金晶, 周绪红, 李俊, 吴曙辉
Journal: BMJ (2008)

低温等离子刀是最先进的低温消融技术,我科将它用于腺样体的切除,具有手术时间短,术中出血少,切除腺样体彻底等优点.我院自2005年6月至2006年4月诊断为腺样体肥大且有手术适应证的患者58例,分别采用低温等离子刀切除术与传统腺样体刮除术,分析对比两种手术方式的优缺点。
Epigenetic control of breast cancer susceptibility.
Authors: Natascia Marino, Rana German, Nakshatri Harikrishna, Ram Podicheti, Ashley Vode, Jun Liu, Jie Huang, Douglas B Rusch, Sha Cao, Anna Maria Storniolo
Journal: Journal of Clinical Oncology (2020)

1560 Background: Epigenetic mechanisms such as DNA methylation are important regulators of gene expression and are frequently dysregulated early in breast carcinogenesis. The relationship between DNA methylation aberrations in normal breast tissue and breast cancer risk remains unclear. Methods: Disease-free breast tissue cores donated by 71 high-risk (Tyrer-Cuzick lifetime risk ≥20%) and 79 average-risk women were obtained from the Komen Tissue Bank and processed for whole methylome (Diagenode's MethylCap Library and single-end 75-bp sequencing on Illumina Nextseq) and whole transcriptome (Illumina Nextseq) profiling. Reads from RNA-seq data were aligned to the human genome reference, GRCh38.p12 using STAR v.2.5.2b and tested for differential gene expression using DESeq2 ver. 1.24.0. For DNA methylation data, difference of variation in deduplicated read coverage among 250-bp fixed sized bins spanning CpG islands between high- and average-risk libraries was computed as z-ratios to identify differentially methylated regions. Pathway analysis was performed using IPA v06_01. Results: We identified 1355 CpGs that were differentially methylated between high- and average-risk breast tissues (ΔZ &gt; 0.5, FDR &lt; 0.05). Hypomethylated CpGs were overrepresented in high-risk tissue and were found predominantly (68%) in non-coding regions. Hypermethylated CpG sites were found equally in the gene body and non-coding regions. Transcriptomic analysis identified 112 differentially expressed genes (fold change≥2, FDR &lt; 0.05), involved in chemokines signaling, metabolism and estrogen biosynthesis. Among those, FAM83A (logfc = 2.3, FDR = 0.004) was previously described as epigenetically dysregulated in multiple cancers and transforms breast epithelial cell in vitro. Methylation-expression correlations revealed 11 epigenetically regulated genes including cellular transformation-associated BMPR1B. Two hypomethylated/upregulated long non-coding RNAs were also identified in high-risk breasts. Conclusions: This is the first gene expression/DNA methylation analysis of normal breasts from women at either high or average risk of breast cancer. Our discovery of epigenetically regulated genes associated with breast cancer risk provides an opportunity to mechanistically dissect breast cancer susceptibility and risk-associated molecular alterations. Unlike the current focus of identifying germline mutations or single nucleotide polymorphisms responsible for higher risk, our studies reveal an epigenetic mechanism, which is not discernable through simple genomic sequencing.
Endogenous TLR2 ligand embedded in the catalytic region of human cysteinyl-tRNA synthetase 1
Authors: Seongmin Cho, Sang Bum Kim, Youngjin Lee, Ee Chan Song, Uijoo Kim, Hyeong Yun Kim, Ji Hun Suh, Peter C Goughnour, YounHa Kim, Ina Yoon, Na Young Shin, Doyeun Kim, Il-Kyu Kim, Chang-Yuil Kang, Song Yee Jang, Myung Hee Kim, Sunghoon Kim
Journal: Journal for ImmunoTherapy of Cancer (2020)

The generation of antigen-specific cytotoxic T lymphocyte (CTL) responses is required for successful cancer vaccine therapy. In this regard, ligands of Toll-like receptors (TLRs) have been suggested to activate adaptive immune responses by modulating the function of antigen-presenting cells (APCs). Despite their therapeutic potential, the development of TLR ligands for immunotherapy is often hampered due to rapid systemic toxicity. Regarding the safety concerns of currently available TLR ligands, finding a new TLR agonist with potent efficacy and safety is needed.A unique structural domain (UNE-C1) was identified as a novel TLR2/6 in the catalytic region of human cysteinyl-tRNA synthetase 1 (CARS1) using comprehensive approaches, including RNA sequencing, the human embryonic kidney (HEK)-TLR Blue system, pull-down, and ELISA. The potency of its immunoadjuvant properties was analyzed by assessing antigen-specific antibody and CTL responses. In addition, the efficacy of tumor growth inhibition and the presence of the tumor-infiltrating leukocytes were evaluated using E.G7-OVA and TC-1 mouse models. The combined effect of UNE-C1 with an immune checkpoint inhibitor, anti-CTLA-4 antibody, was also evaluated in vivo. The safety of UNE-C1 immunization was determined by monitoring splenomegaly and cytokine production in the blood.Here, we report that CARS1 can be secreted from cancer cells to activate immune responses via specific interactions with TLR2/6 of APCs. A unique domain (UNE-C1) inserted into the catalytic region of CARS1 was determined to activate dendritic cells, leading to the stimulation of robust humoral and cellular immune responses in vivo. UNE-C1 also showed synergistic efficacy with cancer antigens and checkpoint inhibitors against different cancer models in vivo. Further, the safety assessment of UNE-C1 showed lower systemic cytokine levels than other known TLR agonists.We identified the endogenous TLR2/6 activating domain from human cysteinyl-tRNA synthetase CARS1. This novel TLR2/6 ligand showed potent immune-stimulating activity with little toxicity. Thus, the UNE-C1 domain can be developed as an effective immunoadjuvant with checkpoint inhibitors or cancer antigens to boost antitumor immunity.
Correlation of PR and ER expression in tumors in various growth patterns of cervical cancer as a prognostic factor.
Authors: Elena P. Ulianova, Diana A. Spiridonova, Vera P. Nikitina, Inna A. Novikova, Aleksandr B. Sagakyants, Evgeniya M. Nepomnyashchaya, Oksana G. Shulgina, Ivan S. Nikitin, Oleg I. Kit
Journal: Journal of Clinical Oncology (2020)

e18031 Background: Cervical cancer is the fourth leading cause of cancer deaths among women worldwide. Since the uterus has receptors through which hormonal effects are realized, studies on the tissue receptor apparatus for estrogen and progesterone are relevant. The purpose of the study was to evaluate the correlation of PR and ER expression as a prognostic factor in cervical cancer. Methods: The study included 60 patients aged 28-65 years diagnosed with cervical cancer. Patients were divided into two groups: group 1 – endophytic pattern of tumor growth (n = 30), group 2 – exophytic pattern (n = 30). Eligibility criteria included morphologically confirmed squamous cell carcinoma of the cervix T1b-2aN0M0, stage I-II. Rabbit monoclonal antibodies for ER (Thermo scientific) and PR (Cell Marque) with the Reveal Polyvalent HRP-DAB Detection System were used for the IHC analysis. Statisical analysis of the results was performed with the Statistica 10 program (StatSoft Inc., USA). Results: The average expression of the ER marker was 5.4±3.03% for group 1 (endophytic tumors) and 13.9±8.2% for group 2 (exophytic tumors). The average PR expression was 0.5±0.3% and 1.6±1.1%, respectively. The maximal accumulation of both PR and ER in the nuclei of tumor cells was registered in patients of group 2, being 3.2 times (p = 0.931) and 2.6 times (p = 0.815) higher than in group 1, respectively. However, the difference was not statistically significant (the Mann-Whitney test, p &gt; 0.05). The Spearman rank correlation test did not show statistically significant correlation between the groups and the markers (r = -0.218, p = 0.338). Statistically significant correlation was observed only in the group with exophytic pattern of tumor growth (r = 0.786, p &lt; 0.01). Conclusions: The IHC analysis revealed a tendency to an increase in the expression of PR and ER in patients with exophytic tumors. However, the correlation between the expression of these indicators cannot be considered as a predictive factor in cervical cancer.